

## Regulatory Announcement

[Go to market news section](#)



**Company** Omega Diagnostics Group PLC  
**TIDM** ODX  
**Headline** Genesis-CNS Interim Results  
**Released** 08:21 31-Aug-07  
**Number** 0649D

31 August 2007

Omega Diagnostics Group PLC (“the Company”)

Omega Diagnostics Group PLC announces that further to yesterday’s Extraordinary General Meeting at which approval was given for the acquisition of Genesis Diagnostics Ltd (“Genesis”) and Cambridge Nutritional Sciences Ltd (“CNS”), the unaudited trading results of Genesis and CNS for the eight months ended 30 June 2007 are provided below. These trading results will not form part of the trading results for Omega Diagnostics Group PLC for its year ended 31 March 2008, since it is only the post-acquisition trading results of Genesis and CNS that will be included.

The figures below are provided as guidance only to shareholders of the trading performance of Genesis and CNS in the year to date. Included within the Genesis results for the eight months to 30 June 2007 is directors’ remuneration of £143,955 (12 months to 31 October 2006: £195,258). These costs cover the remuneration of the two vendor directors, Dr Mike Walker and Mrs Irene Walker. On completion of the acquisitions, these costs will cease with immediate effect although Dr Mike Walker will be appointed a non-executive director of the Company at completion on an annual fee of £15,000.

**GENESIS DIAGNOSTICS LTD**  
**Profit and Loss Account**  
**EIGHT months ended 30 JUNE 2007**

	Unaudited 8 months to 30 June 2007	Audited 12 months to 31 October 2006
	£	£
<b>TURNOVER</b>	<b>1,238,385</b>	<b>1,901,586</b>
Cost of sales	(191,627)	(296,930)
<b>GROSS PROFIT</b>	<b>1,046,758</b>	<b>1,604,656</b>
Selling & distribution costs	(26,105)	(67,992)
Administrative expenses	(880,362)	(1,297,136)
<b>OPERATING PROFIT</b>	<b>140,291</b>	<b>239,528</b>

<b>PROFIT on ordinary activities before interest and taxation</b>	<b>140,291</b>	<b>239,528</b>
Interest Receivable	2,500	3,509
Interest payable	(14,248)	(4,934)
<b>PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION</b>	<b>128,543</b>	<b>238,103</b>

**GENESIS DIAGNOSTICS LTD**  
**Balance Sheet**  
**As at 30 JUNE 2007**

	Unaudited As at 30 June 2007	Audited As at 31 October 2006
	£	£
<b>Assets</b>		
Non-current assets		
Property, Plant and equipment	217,080	254,158
Current Assets		
Stocks	267,915	214,782
Debtors	537,946	423,803
Cash at bank and in hand	159,902	209,613
	<u>965,763</u>	<u>848,198</u>
<b>Total Assets</b>	<u><u>1,182,843</u></u>	<u><u>1,102,356</u></u>
<b>EQUITY AND liabilities</b>		
Equity		
Issued Capital	1,000	1,000
Retained Earnings	1,012,748	884,204
Total equity	<u>1,013,748</u>	<u>885,204</u>
<b>Liabilities</b>		
Non Current Liabilities		
Long term borrowings	26,411	35,359
Deferred taxation	4,418	4,418
	<u>30,829</u>	<u>39,777</u>

## Current Liabilities

Loans & overdrafts	13,259	13,259
Trade and other payables	87,767	126,876
Corporation tax payable	37,240	37,240
	<hr/>	<hr/>
Total Current Liabilities	138,266	177,375
	<hr/>	<hr/>
Total Liabilities	169,095	217,152
	<hr/>	<hr/>
<b>Total equity and liabilities</b>	<b>1,182,843</b>	<b>1,102,356</b>
	<hr/> <hr/>	<hr/> <hr/>

**GENESIS DIAGNOSTICS LTD****Cash Flow Statement****EIGHT months ended 30 JUNE 2007**

	Unaudited 8 months to 30 June 2007	Audited 12 months to 31 October 2006
	£	£
<b>Cash flows generated from operations</b>		
Profit for the year	128,543	197,208
Adjustments for:		
Taxation	-	40,895
Finance costs	14,248	4,934
Finance income	(2,500)	(3,509)
	<hr/>	<hr/>
Operating profit before working capital movement	140,291	239,528
(Increase)/decrease in trade and other receivables	(114,143)	49,976
(increase)/decrease in inventories	(53,133)	(72,941)
(Decrease)/increase in trade and other payables	(39,217)	(60,978)
Depreciation	58,934	99,184
Loss gain on sale of fixed assets	-	4,348
	<hr/>	<hr/>
<b>Net cash flow from operating activities</b>	<b>(7,268)</b>	<b>259,117</b>
	<hr/> <hr/>	<hr/> <hr/>

**Investing Activities**

Finance Income	2,500	3,509
Purchase of property plant and equipment	(21,856)	(191,851)
Proceeds of sales of fixed assets	-	36,969
<b>Net cash used in Investing activities</b>	<b>(19,356)</b>	<b>(151,373)</b>

**Financing activities**

Interest paid	(14,248)	(4,934)
Taxation paid	-	(17,859)
Dividends Paid	-	(45,000)
Payment of finance lease liabilities	(8,839)	(18,466)
<b>Net cash used in financing activities</b>	<b>(23,087)</b>	<b>(86,259)</b>

**Net (decrease)/ increase in cash and cash equivalents**

	(49,711)	21,485
Cash and cash equivalents at beginning of period	209,613	188,128
<b>Cash and cash equivalents at end of period</b>	<b>159,902</b>	<b>209,613</b>

**CAMBRIDGE NUTRITIONAL SCIENCES LTD**  
**Profit and Loss Account**  
**EIGHT months ended 30 JUNE 2007**

	Unaudited 8 months to 30 June 2007	Audited 12 months to 31 October 2006
	£	£
<b>TURNOVER</b>	<b>319,682</b>	<b>289,563</b>
Cost of sales	(74,272)	(64,137)
<b>GROSS PROFIT</b>	<b>245,410</b>	<b>225,426</b>
Selling & distribution costs	(45,436)	(25,674)
Administrative expenses	(39,163)	(121,717)

<b>OPERATING PROFIT</b>	<b>160,811</b>	<b>78,035</b>
<b>PROFIT on ordinary activities before interest and taxation</b>	<b>160,811</b>	<b>78,035</b>
Interest Receivable	2,100	1,439
Interest payable	(3,961)	-
<b>PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION</b>	<b>158,950</b>	<b>79,474</b>

**CAMBRIDGE NUTRITIONAL SCIENCES LTD**  
**Balance Sheet**  
**As at 30 JUNE 2007**

	Unaudited As at 30 June 2007	Audited As at 31 October 2006
	£	£
<b>Assets</b>		
Non-current assets		
Property, Plant and equipment	32,778	39,331

<b>Current Assets</b>		
Stocks	55,209	8,028
Debtors	42,086	47,547
Cash at bank and in hand	198,877	49,743
	<u>296,172</u>	<u>105,318</u>
<b>Total Assets</b>	<u>328,950</u>	<u>144,649</u>
<b>EQUITY AND liabilities</b>		
<b>Equity</b>		
Issued Capital	100	100
Retained Earnings	280,265	121,314
	<u>280,365</u>	<u>121,414</u>
<b>Liabilities</b>		
<b>Non Current Liabilities</b>		
Deferred taxation	1,369	1,369
	<u>1,369</u>	<u>1,369</u>
<b>Current Liabilities</b>		
Trade and other payables	33,003	7,653
Corporation tax payable	14,213	14,213
	<u>47,216</u>	<u>21,866</u>
<b>Total Current Liabilities</b>	<u>47,216</u>	<u>21,866</u>
<b>Total Liabilities</b>	<u>48,585</u>	<u>23,235</u>
<b>Total equity and liabilities</b>	<u>328,950</u>	<u>144,649</u>

**CAMBRIDGE NUTRITIONAL SCIENCES LTD**  
**Cash Flow Statement**  
**EIGHT months ended 30 JUNE 2007**

Unaudited

Audited

8 months to  
30 June 2007

12 months to  
31 October 2006

£

£

**Cash flows generated from operations**

Profit for the year	158,950	63,904
Adjustments for:		
Taxation	-	15,570
Finance costs	3,961	-
Finance income	(2,100)	(1,439)
	<hr/>	<hr/>
Operating profit before working capital movement	160,811	78,035
Decrease/(increase) in trade and other receivables	5,459	(27,807)
(increase)/decrease in inventories	(47,181)	(89)
increase in trade and other payables	25,351	1,488
Depreciation	6,555	13,111
	<hr/>	<hr/>
<b>Net cash flow from operating activities</b>	<b>150,995</b>	<b>64,738</b>

**Investing Activities**

Finance Income	2,100	1,439
Purchase of property plant and equipment	-	(37,619)
	<hr/>	<hr/>
<b>Net cash used in Investing activities</b>	<b>2,100</b>	<b>(36,180)</b>

**Financing activities**

Interest paid	(3,961)	-
Taxation paid	-	(2,086)
	<hr/>	<hr/>
<b>Net cash used in financing activities</b>	<b>(3,961)</b>	<b>(2,086)</b>

**Net increase in cash and cash equivalents**

Cash and cash equivalents at beginning of period	49,743	23,271
	<hr/>	<hr/>
<b>Cash and cash equivalents at end of period</b>	<b>198,877</b>	<b>49,743</b>

Contacts:

Omega Diagnostics Group PLC  
Tel: 01259 763030

Andrew Shepherd, Chief Executive  
Kieron Harbinson, Finance Director  
[www.omegadiagnostics.com](http://www.omegadiagnostics.com)

Landsbanki Securities (UK) Limited  
Nominated Adviser & Broker  
Tel: 020 7426 9000

Thilo Hoffmann/Simon Brown, Corporate Finance

Parkgreen Communications Limited  
Paul McManus  
Tel: 020 7479 7933  
Mob: 07980 541 893  
**paul.mcmanus@parkgreenmedia.com**

END

Close

**London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.**

©2007 London Stock Exchange plc. All rights reserved